Aristides Capital LLC Acquires New Position in Progyny, Inc. (NASDAQ:PGNY)

Aristides Capital LLC bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY) during the fourth quarter, HoldingsChannel.com reports. The firm bought 14,200 shares of the company’s stock, valued at approximately $245,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its stake in shares of Progyny by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,446 shares of the company’s stock valued at $11,287,000 after acquiring an additional 4,007 shares in the last quarter. State Street Corp raised its position in Progyny by 4.5% in the 3rd quarter. State Street Corp now owns 3,113,654 shares of the company’s stock valued at $52,185,000 after purchasing an additional 134,861 shares in the last quarter. Wolverine Trading LLC boosted its stake in shares of Progyny by 131.5% in the 3rd quarter. Wolverine Trading LLC now owns 19,677 shares of the company’s stock valued at $331,000 after buying an additional 11,177 shares during the period. Wellington Management Group LLP grew its position in shares of Progyny by 4.0% during the third quarter. Wellington Management Group LLP now owns 430,300 shares of the company’s stock worth $7,212,000 after buying an additional 16,638 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Progyny during the third quarter worth approximately $469,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Canaccord Genuity Group boosted their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, February 28th. BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Monday, March 31st. Bank of America raised their price target on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. upped their price objective on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $23.64.

Progyny Stock Performance

Progyny stock opened at $22.60 on Monday. The stock has a 50-day simple moving average of $22.19 and a 200-day simple moving average of $18.45. The company has a market capitalization of $1.93 billion, a P/E ratio of 38.97, a PEG ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $36.36.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.